+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients



Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients



Drug and Alcohol Review 30(6): 613-620



To examine Australian opioid substitution treatment (OST) prescribers' perceptions of (i) diversion and/or injection of methadone, buprenorphine, buprenorphine-naloxone by patients; and (ii) effectiveness of current treatment policies in minimising the associated risks. 1278 authorised OST prescribers, identified by each jurisdiction's health department records, were sent a postal survey in 2007. Reminder letters and additional copies of the survey were sent to non-responders at weeks four and eight following the initial mail-out. Respondents went into a draw to win one of ten $100 book vouchers. Although the response rate was 26% (N = 291), participating prescribers served half (49%) of all OST patients in Australia. Prescribers perceived more buprenorphine patients removed supervised doses (7%) and diverted unsupervised doses (20%), compared with methadone patients (1% and 4% respectively) and buprenorphine-naloxone patients (3% and 2% respectively). Prescribers reported significantly more buprenorphine and buprenorphine-naloxone patients injected doses (5% respectively), compared with methadone patients (2%). Non-adherence was identified through patient self-report (51%), and the reports of pharmacists (49%) and other staff (34%). More prescribers were confident in assessing the risk of injection (54%) than diversion (37%). Many prescribers responded 'don't know' to quantitative survey items. Qualitative responses highlighted uncertainties in assessing diversion/injection and whether current responses constituted 'best practice'. Australian prescribers perceive most patients adhere with OST, although they may underestimate the levels of diversion. Prescribers' beliefs about patients' behaviours are important and influence decisions to prescribe, medication choice and suitability for unsupervised dosing. The uncertainties in assessing and responding to diversion/injection may be a factor deterring prescribers' participation in OST.

(PDF emailed within 0-6 h: $19.90)

Accession: 055139801

Download citation: RISBibTeXText

PMID: 21355939

DOI: 10.1111/j.1465-3362.2010.00274.x


Related references

Diversion of methadone and buprenorphine from opioid substitution treatment: patients who regularly sell or share their medication. Journal of Addictive Diseases 34(1): 1-17, 2016

Diversion of methadone and buprenorphine from opioid substitution treatment: the importance of patients' attitudes and norms. Journal of Substance Abuse Treatment 54: 50-55, 2016

Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors. International Journal on Drug Policy 26(2): 183-190, 2015

Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience. Journal of Public Health 38(3): E368-E374, 2015

Medication-Assisted Opioid Treatment Prescribers in Federally Qualified Health Centers: Capacity Lags in Rural Areas. Journal of Rural Health 34(1): 14-22, 2017

Perceptions and practices addressing diversion among US buprenorphine prescribers. Drug and Alcohol Dependence 186: 147-153, 2018

Perceptions and practices addressing diversion among US buprenorphine prescribers. Drug and Alcohol Dependence 186: 147-153, 2018

Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective. Journal of Psychoactive Drugs 46(5): 427-435, 2015

Methods and motivations for buprenorphine diversion from public opioid substitution treatment clinics. Journal of Addictive Diseases 28(1): 57-63, 2009

The Impact of Misuse and Diversion of Opioid Substitution Treatment Medicines: Evidence Review and Expert Consensus. European Addiction Research 22(2): 99-106, 2016

Prescribers' perceptions of medication discontinuation: survey instrument development and validation. American Journal of Managed Care 22(11): 747-754, 2018

Clients' perceptions of opioid substitution treatment: an input to improving the quality of treatment. International Journal of Mental Health Nursing 21(4): 330-339, 2012

The causal effect of opioid substitution treatment on HAART medication refill adherence. Aids 29(8): 965-973, 2016

Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients. International Journal on Drug Policy 26(9): 875-882, 2016

Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia. Substance Use and Misuse 45(1-2): 240-252, 2010